INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 2)
Photo: https://unsplash.com/photos/Yta-zdP9PVM

INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 2)

Before you read on, make sure to check out Part 1 of our article. In Part 1, Green Bay Packers Cornerback Shemar Jean-Charles discusses why he supports the Alzheimer's Association and how…

Continue Reading INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 2)
Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
source: pixabay.com

Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation

According to a story from BioSpace, Ziopharma Oncology, Inc. has recently announced that its investigational therapy Ad-RTS-hIL-12 with veledimex (also called Controlled IL-12) has been given Rare Pediatric Disease designation…

Continue Reading Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
A Teenager’s Plan to Help her Friend with Diffuse Intrinsic Pontine Glioma Takes Off
source: pixabay.com

A Teenager’s Plan to Help her Friend with Diffuse Intrinsic Pontine Glioma Takes Off

According to a story from Essex Live, Lily Wythe is a fourteen year old girl who was recently diagnosed with a rare form of brain cancer called diffuse intrinsic pontine…

Continue Reading A Teenager’s Plan to Help her Friend with Diffuse Intrinsic Pontine Glioma Takes Off
Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
sbtlneet / Pixabay

Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

According to a story from BioSpace, Oncotelic, Inc., recently announced the publication of a study in the Journal of Clinical Research in Pediatrics. This study appears to back up the therapeutic…

Continue Reading Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation
geralt / Pixabay

Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation

According to a story from Biotech 365, the immuno-oncology company Mateon Therapeutics Inc. has recently announced that the company's investigational product candidate OT101 has earned the US Food and Drug…

Continue Reading Experimental Treatment for Diffuse Intrinsic Pontine Glioma Earns Rare Pediatric Disease Designation

New Drug Has Promise for Treating Diffuse Intrinsic Pontine Glioma and Fibrodysplasia Ossificans Progressiva

Diffuse Intrinsic Pontine Glioma Diffuse intrinsic pontine glioma (DIPG) is a rare form of childhood brain cancer that has a 100% mortality rate. Children diagnosed with DIPG only typically live…

Continue Reading New Drug Has Promise for Treating Diffuse Intrinsic Pontine Glioma and Fibrodysplasia Ossificans Progressiva